Renalis Raises $824K to Accelerate its Digital Health Platform
- Funding

Renalis Raises $824K to Accelerate its Digital Health Platform

Healthcare Startup, Renalis, Raises $824K to Accelerate its Digital Health Platform.

Renalis provides innovative digital therapy solutions to treat patients with pelvic health disorders.

The Healthcare Collaboration Fund is managed through a partnership between Cleveland-based Venture Investor JumpStart Inc and University Hospitals Ventures, University Hospitals’ innovation and commercialization arm. The round also includes participation from JumpStart Inc. as well as a mix of individual and private investors.

“Renalis in tackling a significant unmet need in pelvic health management,” said Hardik Desai, Sr. Investing Partner at JumpStart. “We are excited to partner with UH and Renalis to commercialize this important technology.”

“Renalis has an opportunity to address very prevalent and debilitating pelvic health conditions,” said Neil Wyant, Managing Director of UH Ventures. “Our investment enables UH to be its ‘living laboratory’ so that we can prove out Renalis’ novel approach and have an even bigger impact on patient care.”

Renalis’ first digital therapeutic product, “CeCe,” enables patients to record and manage symptoms of Overactive Bladder (OAB) via a mobile application.  The new funds will be used to amplify the research within healthcare systems like UH, support regulatory efforts, and strategically build a team to lead commercialization and technology efforts moving forward.

“We are so grateful for this latest funding round,” said Renalis CEO, Missy Lavender. “We can now accelerate our go-to-market plan to deliver evidence-based solutions to chronic, expensive, and prevalent conditions like OAB to millions of patients in the U.S. and beyond.”

 


Renalis  is a Cleveland-based company committed to developing FDA-approved prescription digital therapeutics to treat pelvic health disorders.  The company was founded in 2017 by Missy Lavender, who has suffered from pelvic health disorders, including OAB, since her first child twenty years ago.  Renalis’ first commercial platform is a digital therapeutics for Overactive Bladder (OAB), which affects over 33 million Americans.  In the future, the company plans to launch therapeutics for menstrual disorders, stress incontinence, bowel dysfunction, and chronic pelvic pain, as well as, when applicable, will target solutions for all persons with a pelvis.

Contact:
Missy Lavender (312) 287-1951
missy@renalis.health

Related Links

https://www.renalis.health

Renalis Raises $824K to Accelerate its Digital Health Platform

Jobs in Digital Health

close
Exploring the Innovations Shaping Digital Health

Join the Club

Every week, we'll be sending you curated materials handpicked for Digital Health Professionals - open calls, accelerator deadlines, and more... 

Plus, you'll be the first to know about our discounts!

We don’t spam! Read our privacy policy for more info.